CN1184667A - Traditional Chinese medicinal leukogenic prepn. - Google Patents
Traditional Chinese medicinal leukogenic prepn. Download PDFInfo
- Publication number
- CN1184667A CN1184667A CN97120998A CN97120998A CN1184667A CN 1184667 A CN1184667 A CN 1184667A CN 97120998 A CN97120998 A CN 97120998A CN 97120998 A CN97120998 A CN 97120998A CN 1184667 A CN1184667 A CN 1184667A
- Authority
- CN
- China
- Prior art keywords
- prepn
- chinese medicine
- traditional chinese
- chinese medicinal
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of traditional Chinese medicinal prepn. for elucopenia. The recipe (by wt.%) consists of: oldenlandia 30-55, root of membranous milk vetch 30-55, sealwort 15-40. Through the process of mixing, decocting, removing dregs, concentrating, adding excipient and adding flavouring, various traditional Chinese medicinal prepns. are made up. Through the clinical trial, said prepn. can improve the leucopenia, increase the leucocyte, improve the circulatation of marrow, enhance the immunocompetence and there is no any toxic side effect.
Description
The invention belongs to Chinese herbal and crude drugs preparations, relate in particular to a kind of Chinese medicine preparation of leukocyte increasing auxiliary for treating cancer.
The cancer method of treatment at present has four classes, i.e. operation, radiotherapy, chemotherapy and immunization therapy, the therapeutic alliance of these four kinds of methods has obtained great success, but chemotherapy can cause patient's bone marrow injury and leukopenia occur, and it is quite common clinically, nearly all patient all can occur, and most patients are also very serious to force chemotherapy to stop.How to make the very fast rising of leukocyte of decline, finish chemotherapy treatment, strengthen therapeutic effect, this also is a problem that is worth research in the chemotherapy at present, also is to desire the difficulty of being captured in the chemotherapy field.China's cancer morbidity is very high at present, and according to statistics in 1991, cancer took place annual about 1,250,000 people of China, about 900,000 people's death, these people all leukopenia can occur in chemotherapy, so research rises white method, seeking and rise the real necessity that belongs to of BAIYAO product, also is the task of top priority.The invention disclosed patent has at present: " Shengbaisan powder medicine for umbilicus and preparation using method " CN1131026A, " a kind of medicine for benefitting Qi, removing cancer and raising leucocyte and preparation method " CN1138476A, the CN1090191A that " is used to improve human leukocytes, hematoblastic Chinese patent medicine and preparation technology ", " restorative extract for raising leucocyte count " CN1081901A etc., but above-mentioned prior art effect is not satisfactory.
The objective of the invention is deficiency at above-mentioned prior art, from causing the Mechanism Study leukopenia of the bone marrow injury that cancer chemotherapy causes, the microcirculation that is mainly bone marrow suffers damage, cause that with chemotherapy in the past the infringement of bone marrow is that impaired this viewpoint of hematopoietic stem cell of bone marrow has different opinions, it is a kind of new viewpoint, to the treatment bone marrow injury, improve quantity of leucocyte, developed a kind of new white Chinese medicine preparation of the liter that has no side effect.
The object of the present invention is achieved like this: to improve the microcirculatory method of bone marrow, based on traditional Chinese medical science blood circulation promoting and blood stasis dispelling, nourishing kidney water, developed the white Chinese medicine preparation of a kind of liter, the prescription of said preparation is (percentage by weight): Herba Hedyotidis Diffusae 30-55%, Radix Astragali 30-55%, Rhizoma Polygonati 15-40% through mixing decocting in water, removes slag, concentrate, add the figuration flavoring agent,, make Chinese medicine preparation such as injection, tablet, oral liquid, capsule as white sugar, starch etc.
The white Chinese medicine preparation clinical trial result of liter of the present invention: to 19 routine comparing property of leukopenia caused by cancer chemotherapy disease GP TH researchs, the result all obtains promising result with the kidney invigorating Chinese herbal medicine and Western medicine 654-II treatment group.19 examples are selected in treatment research, male 13 examples, and women 6 examples are divided into three treatment groups.General to rise white treatment group 6 examples be matched group, uses batyl alcohol 50mg, and January three times is oral, leucogen 20mg, and three times on the one are oral, treat two weeks, Chinese herbal treatment group 7 examples, use Chinese medicine formula, and decocting in water is obeyed potion every day, treats for two weeks.3 examples of 654-II treatment group 7 examples and 654-II treatment group are being done the bone marrow analysis, and the bone marrow smear preceding with treatment compares, and observes the bone marrow recovery situation.
Curative effect determinate standard (4): total white blood cells rises to 4 * 10 in the week
9/ L is above to be produce effects, rises to 4 * 10 in two weeks
9/ L is above to be effectively, is lower than 4 * 10 in two weeks
9/ L is invalid.The results are shown in Table 1, table 2.
Table 1:
The paired observation of three treatment group therapeutic effect
| Group | Total white blood cells * 10 9/L | Produce effects | Effectively | Invalid | ||
| Before the treatment | Treat a week | Treated for two weeks | ||||
| Chinese herbal medicine group (7 example) | ??2.582 | ??4.014 | ??5.485 | ??4 | ??2 | ??1 |
| 654-2 organizes (6 example) | ??2.775 | ??4.166 | ??5.800 | ??3 | ??1 | ??2 |
| Matched group (6 example) | ??2.966 | ??2.983 | ??2.783 | ??0 | ??1 | ??5 |
Table 2:
The recovery of Chinese herbal treatment and 654-II group treatment back bone marrow granulocyte series changes
| The cell title | (12 example) meansigma methods before the treatment | Chinese drug-treated group treatment back (7 example) meansigma methods | 654-II treatment back (5 example) meansigma methods |
| Myeloblast | ????0.73 | ????0.78 | ????0.33 |
| Promyelocyte | ????6.18 | ????5.64 | ????6.83 |
| Children's grain in the neutrality | ????10.86 | ????10.14 | ????11.33 |
| Young of neutral evening | ????10.72 | ????13.21↑ | ????11.00↑ |
| Neutral band form nucleus | ????9.27 | ????10.92↑ | ????10.16↑ |
| Neutral leaflet nuclear | ????10.36 | ????12.50↑ | ????11.83↑ |
| Eosinophilic granulocyte | ????1.59 | ????2.35↑ | ????2.83↑ |
| Have a liking for the alkali granulocyte | ????0.68 | ????0.42 | ????0.33 |
Proved with the kidney invigorating Chinese herbal treatment from table 1, table 2 destructive microcirculation can significantly be recovered and take a turn for the better.Treat aplastic anemia with anisodamine, can improve the bone marrow microcirculation, aplastic anemia is taken a turn for the better.Above basic research and clinical practice prove, form prescription to leukopenia caused by cancer chemotherapy disease with the kidney invigorating Chinese herbal medicine pointedly, and curative effect is all felt quite pleased as a result.The curative effect that obtains by this tentative treatment proves, has confirmed the microcirculatory infringement of bone marrow just of leukopenia caused by cancer chemotherapy disease more.All have no side effect with rising white Chinese medicine preparation by the clinical practice proof.
Embodiment one: Herba Hedyotidis Diffusae 55%, the Radix Astragali 30%, Rhizoma Polygonati 15%.
Embodiment two: Herba Hedyotidis Diffusae 30%, the Radix Astragali 55%, Rhizoma Polygonati 15%.
Embodiment three: Herba Hedyotidis Diffusae 30%, the Radix Astragali 30%, Rhizoma Polygonati 40%.
By above-mentioned prescription, claim complete putting in the enamel extraction pot with Herba Hedyotidis Diffusae, the Radix Astragali, Rhizoma Polygonati, use the distilled water lixiviate, filtrate is collected in steaming and decocting, filtration, and then decoct with distilled water, merging filtrate concentrates, and adds the figuration flavoring agent, as white sugar, starch etc., can be made into various injections, tablet, oral liquid, capsule etc.
Claims (2)
1, the white Chinese medicine preparation of a kind of liter is characterized in that the prescription of this Chinese medicine preparation is (percentage by weight): Herba Hedyotidis Diffusae 30-55%, Radix Astragali 30-55%, Rhizoma Polygonati 15-40%, through mixing decocting in water, remove slag, concentrate, add the figuration flavoring agent and make injection, tablet, Chinese medicine preparation such as oral liquid, capsule.
2, the white Chinese medicine preparation of liter as claimed in claim 1 is characterized in that described figuration flavoring agent, is white sugar, starch etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97120998A CN1063076C (en) | 1997-12-09 | 1997-12-09 | Traditional Chinese medicinal leukogenic prepn. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97120998A CN1063076C (en) | 1997-12-09 | 1997-12-09 | Traditional Chinese medicinal leukogenic prepn. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1184667A true CN1184667A (en) | 1998-06-17 |
| CN1063076C CN1063076C (en) | 2001-03-14 |
Family
ID=5176124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97120998A Expired - Fee Related CN1063076C (en) | 1997-12-09 | 1997-12-09 | Traditional Chinese medicinal leukogenic prepn. |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1063076C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884730B (en) * | 2010-05-21 | 2012-07-25 | 吉林大学 | Chinese medicinal preparation for treating hypoproteinemia caused by liver damage |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085409A (en) * | 1992-09-19 | 1994-04-20 | 黄琼林 | Schizandrol |
| CN1099993A (en) * | 1994-04-08 | 1995-03-15 | 蓝烈风 | Biological immunopotentiator "Kangaiping" |
-
1997
- 1997-12-09 CN CN97120998A patent/CN1063076C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1063076C (en) | 2001-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103405577B (en) | The Pharmaceutical composition of a kind of enhancing immunity, fatigue alleviating | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1063076C (en) | Traditional Chinese medicinal leukogenic prepn. | |
| CN107854565B (en) | Anti-radiation traditional Chinese medicine composition | |
| CN1051462C (en) | "Yuanshen" pill-medicine for treatment of encephalatrophy | |
| CN1106690A (en) | Medicine of curing hepatitis | |
| CN101953986B (en) | Method for preparing Chinese medicinal preparation for treating Qi deficiency and blood deficiency | |
| CN115006336A (en) | Plant shampoo capable of preventing hair loss, strengthening hair, removing dandruff and relieving itching and preparation method thereof | |
| CN101224226B (en) | Novel clinical uses of big nilgiri nettle | |
| CN1260209A (en) | Medicine for nephritis | |
| CN112076268A (en) | Traditional Chinese medicine lotion for preventing and treating alopecia and blackening hair, preparation method and application | |
| CN1140281C (en) | Yiyuansan powder as one orally taken medicine for treating liver cancer and its preparation | |
| CN114224936B (en) | Extraction and purification process of effective part of white ginseng prescription for increasing leucocyte | |
| CN108079113A (en) | A kind of pharmaceutical composition for treating the postpartum deficiency of blood and preparation method thereof | |
| CN103393954A (en) | Preparation method of ointment for helping rehabilitation of peroneal nerve injury | |
| CN111388604B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN111759940B (en) | Pharmaceutical composition for treating sicca syndrome and preparation method and application thereof | |
| CN111481631B (en) | Traditional Chinese medicine composition for enhancing immunity and resisting fatigue and preparation method thereof | |
| CN102727749B (en) | Medicine for treating aplastic anemia | |
| CN107029111B (en) | Traditional Chinese medicine compound preparation for treating leukemia caused by vital qi deficiency and pathogenic factor latent and preparation method thereof | |
| CN106421154A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing Chinese eaglewood wood and having cell repairing, anti-aging and anti-canter functions as well as preparation method of traditional Chinese medicine composition | |
| CN108066599B (en) | Composition for enhancing immunity and assisting in radiation resistance and preparation method and application thereof | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN114224975A (en) | Composition and medicine for strengthening brain and tonifying kidney as well as preparation method and application of composition and medicine | |
| CN116617339A (en) | Liver-protecting traditional Chinese medicine composition and preparation method and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |